Dhiraj Mannar

Dhiraj Mannar

Auto-generated profile, based on publicly available information

Dhiraj Mannar

Department of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Science
Verified
Journal Article
Open access
DMDhiraj Mannar
Dhiraj Mannar
JSJames W. Saville
James W. Saville
XZXing Zhu
Xing Zhu
SSShanti S. Srivastava
Shanti S. Srivastava
ABAlison M. Berezuk
Alison M. Berezuk
SSSriram Subramaniam
Sriram Subramaniam
The newly reported Omicron variant is poised to replace Delta as the most prevalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant across the world. Cryo–electron microscopy (cryo-EM) structural analysis of the Omicron variant spike protein in complex with human angiotensin-converting enzyme 2 (ACE2) reveals new salt bridges and hydrogen bonds formed by mutated residues arginine-493, serine-496, and arginine-498 in the receptor binding domain with ACE2. These interactions appear to compensate for other Omicron mutations such as the substitution of asparagine for lysine at position 417 (K417N) that are known to reduce ACE2 binding affinity, resulting in similar biochemical ACE2 binding affinities for the Delta and Omicron variants. Neutralization assays show that pseudoviruses that display the Omicron spike protein exhibit increased antibody evasion. The increase in antibody evasion and the retention of strong interactions at the ACE2 interface thus represent important molecular features that likely contribute to the rapid spread of the Omicron variant.

29 April 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
XZXing Zhu
Xing Zhu
DMDhiraj Mannar
Dhiraj Mannar
SSShanti S. Srivastava
Shanti S. Srivastava
ABAlison M. Berezuk
Alison M. Berezuk
JDJean-Philippe Demers
Jean-Philippe Demers
SSSriram Subramaniam
Sriram Subramaniam
The recently reported “UK variant” (B.1.1.7) of SARS-CoV-2 is thought to be more infectious than previously circulating strains as a result of several changes, including the N501Y mutation. We present a 2.9-Å resolution cryo-electron microscopy (cryo-EM) structure of the complex between the ACE2 receptor and N501Y spike protein ectodomains that shows Y501 inserted into a cavity at the binding interface near Y41 of ACE2. This additional interaction provides a structural explanation for the increased ACE2 affinity of the N501Y mutant, and likely contributes to its increased infectivity. However, this mutation does not result in large structural changes, enabling important neutralization epitopes to be retained in the spike receptor binding domain. We confirmed this through biophysical assays and by determining cryo-EM structures of spike protein ectodomains bound to 2 representative potent neutralizing antibody fragments.

1 October 2020 in Cell
Verified
Journal Article
Closed access
WLWei Li
Wei Li
ASAlexandra Schäfer
Alexandra Schäfer
SKSwarali S. Kulkarni
Swarali S. Kulkarni
XLXianglei Liu
Xianglei Liu
DMDavid R. Martinez
David R. Martinez
DDDimiter S. Dimitrov
Dimiter S. Dimitrov

4 December 2021 in Cell Reports
Verified
Journal Article
Open access
DMDhiraj Mannar
Dhiraj Mannar
JSJames W. Saville
James W. Saville
XZXing Zhu
Xing Zhu
SSShanti S. Srivastava
Shanti S. Srivastava
ABAlison M. Berezuk
Alison M. Berezuk
SSSriram Subramaniam
Sriram Subramaniam
The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Beta (B.1.351) and Gamma (P.1) variants of concern (VoCs) include a key mutation (N501Y) found in the Alpha (B.1.1.7) variant that enhances affinity of the spike protein for its receptor, angiotensin-converting enzyme 2 (ACE2). Additional mutations are found in these variants at residues 417 and 484 that appear to promote antibody evasion. In contrast, the Epsilon variants (B.1.427/429) lack the N501Y mutation yet exhibit antibody evasion. We have engineered spike proteins to express these receptor binding domain (RBD) VoC mutations either in isolation or in different combinations and analyze the effects using biochemical assays and cryoelectron microscopy (cryo-EM) structural analyses. Overall, our findings suggest that the emergence of new SARS-CoV-2 variant spikes can be rationalized as the result of mutations that confer increased ACE2 affinity, increased antibody evasion, or both, providing a framework to dissect the molecular factors that drive VoC evolution.

26 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDhiraj Mannar
Dhiraj Mannar
JSJames W Saville
James W Saville
XZXing Zhu
Xing Zhu
SSShanti S. Srivastava
Shanti S. Srivastava
ABAlison M. Berezuk
Alison M. Berezuk
SSSriram Subramaniam
Sriram Subramaniam
Summary: The recently emerged SARS-CoV-2 South African (B. 1.351) and Brazil/Japan (P.1) variants of concern (VoCs) include a key mutation (N501Y) found in the UK variant that enhances affinity of the spike protein for its receptor, ACE2. Additional mutations are found in these variants at residues 417 and 484 that appear to promote antibody evasion. In contrast, the Californian VoCs (B.1.427/429) lack the N501Y mutation, yet exhibit antibody evasion. We engineered spike proteins to express these RBD VoC mutations either in isolation, or in different combinations, and analyzed the effects using biochemical assays and cryo-EM structural analyses. Overall, our findings suggest that the emergence of new SARS-CoV-2 variant spikes can be rationalized as the result of mutations that confer either increased ACE2 affinity, increased antibody evasion, or both, providing a framework to dissect the molecular factors that drive VoC evolution.

4 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDhiraj Mannar
Dhiraj Mannar
KLKaroline Leopold
Karoline Leopold
SSSriram Subramaniam
Sriram Subramaniam
The SARS-CoV-2 spike glycoprotein is a focal point for vaccine immunogen and therapeutic antibody design, and also serves as a critical antigen in the evaluation of immune responses to COVID-19. A common feature amongst enveloped viruses such as SARS-CoV-2 and HIV-1 is the propensity for displaying host-derived glycans on entry spike proteins. Similarly displayed glycosylation motifs can serve as the basis for glyco-epitope mediated cross-reactivity by antibodies, which can have important implications on virus neutralization, antibody-dependent enhancement (ADE) of infection, and the interpretation of antibody titers in serological assays. From a panel of nine anti-HIV-1 gp120 reactive antibodies, we selected two (PGT126 and PGT128) that displayed high levels of cross-reactivity with the SARS-CoV-2 spike. We report that these antibodies are incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and are unlikely to mediate ADE via FcγRII receptor engagement. Nevertheless, ELISA and other immunoreactivity experiments demonstrate these antibodies are capable of binding the SARS-CoV-2 spike in a glycan-dependent manner. These results contribute to the growing literature surrounding SARS-CoV-2 S cross-reactivity, as we demonstrate the ability for cross-reactive antibodies to interfere in immunoassays.